Arbutus Biopharma (NASDAQ: ABUS) revenue
Arbutus Biopharma reported revenue of $14.1m for fiscal 2025, 128.2% more than in fiscal 2024 ($6.2m). Since fiscal 2016 its revenue has grown by 844.5%, an average growth of 28.3% a year.
Arbutus Biopharma's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2024, −66.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $14.1m | +128.2% | −$38.2m | −271.0% |
| 2024 | $6.2m | −66.0% | −$76.3m | −1,236.7% |
| 2023 | $18.1m | −53.5% | −$78.1m | −430.5% |
| 2022 | $39.0m | +255.1% | −$65.5m | −167.8% |
| 2021 | $11.0m | +58.9% | −$73.5m | −669.1% |
| 2020 | $6.9m | +15.0% | −$57.8m | −836.1% |
| 2019 | $6.0m | +1.1% | −$143.9m | −2,394.0% |
| 2018 | $5.9m | −44.4% | −$89.8m | −1,510.2% |
| 2017 | $10.7m | +617.6% | −$110.9m | −1,036.7% |
| 2016 | $1.5m | — | −$491.6m | −32,973.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arbutus Biopharma revenue compared with its sector
By revenue for its latest fiscal year, Arbutus Biopharma ranks 361st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arbutus Biopharma, 128.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 359th | Lineage Cell Therapeutics | $14.6m | 53.2% |
| 360th | Opus Genetics | $14.2m | 29.1% |
| 361st | Arbutus Biopharma | $14.1m | 128.2% |
| 362nd | Hyperfine | $13.6m | 5.2% |
| 363rd | Tonix Pharmaceuticals | $13.1m | 29.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Arbutus Biopharma
- How much revenue did Arbutus Biopharma make in fiscal 2025?
- Arbutus Biopharma reported revenue of $14.1m for fiscal 2025, compared with $6.2m in fiscal 2024.
- How much has the revenue of Arbutus Biopharma grown?
- Between fiscal 2016 and fiscal 2025 it went from $1.5m to $14.1m: 844.5% more, an average growth of 28.3% a year.
- What was the best year for revenue at Arbutus Biopharma?
- Of its last 10 fiscal years, fiscal 2022, with $39.0m.
- Where does Arbutus Biopharma rank in its sector by revenue?
- It ranks 361st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Arbutus Biopharma come from?
- From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Arbutus Biopharma: the Arbutus Biopharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.